uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Cunningham, Janet
Alternative names
Publications (10 of 19) Show all publications
Just, D., Manberg, A., Lindholm Carlström, E., Cunningham, J. & Nilsson, P. (2018). TOWARDS MOLECULAR INSIGHTS INTO PSYCHIATRIC DISORDERS USING AFFINITY PROTEOMICS. Paper presented at 6th Biennial Conference of the Schizophrenia-International-Research-Society (SIRS), APR 04-08, 2018, Florence, ITALY. Schizophrenia Bulletin, 44, S223-S223
Open this publication in new window or tab >>TOWARDS MOLECULAR INSIGHTS INTO PSYCHIATRIC DISORDERS USING AFFINITY PROTEOMICS
Show others...
2018 (English)In: Schizophrenia Bulletin, ISSN 0586-7614, E-ISSN 1745-1701, Vol. 44, p. S223-S223Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
OXFORD UNIV PRESS, 2018
National Category
Psychiatry
Identifiers
urn:nbn:se:uu:diva-357174 (URN)000429541800539 ()
Conference
6th Biennial Conference of the Schizophrenia-International-Research-Society (SIRS), APR 04-08, 2018, Florence, ITALY
Available from: 2018-08-14 Created: 2018-08-14 Last updated: 2018-08-14Bibliographically approved
Sundberg, I., Lannergård, A., Ramklint, M. & Cunningham, J. (2017). Inflammatory Cytokines in a Repeated Measures Prospective Case Study of Interferon-Induced Depression. Paper presented at 72nd Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry (SOBP), MAY 18-20, 2017, San Diego, CA. Biological Psychiatry, 81(10), S399-S399
Open this publication in new window or tab >>Inflammatory Cytokines in a Repeated Measures Prospective Case Study of Interferon-Induced Depression
2017 (English)In: Biological Psychiatry, ISSN 0006-3223, E-ISSN 1873-2402, Vol. 81, no 10, p. S399-S399Article in journal, Meeting abstract (Other academic) Published
Keywords
Interferon-induced depression, Depression, Melatonin, Cytokines and Chemokines, Hepatitis C
National Category
Psychiatry
Identifiers
urn:nbn:se:uu:diva-331809 (URN)10.1016/j.biopsych.2017.02.713 (DOI)000400348701079 ()
Conference
72nd Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry (SOBP), MAY 18-20, 2017, San Diego, CA
Available from: 2017-10-18 Created: 2017-10-18 Last updated: 2017-10-18Bibliographically approved
Edvinsson, Å., Bränn, E., Hellgren, C., Freyhult, E., White, R., Kamali-Moghaddam, M., . . . Sundström Poromaa, I. (2017). Lower inflammatory markers in women with antenatal depression brings the M1/M2 balance into focus from a new direction. Psychoneuroendocrinology, 80, 15-25
Open this publication in new window or tab >>Lower inflammatory markers in women with antenatal depression brings the M1/M2 balance into focus from a new direction
Show others...
2017 (English)In: Psychoneuroendocrinology, ISSN 0306-4530, E-ISSN 1873-3360, Vol. 80, p. 15-25Article in journal (Refereed) Published
Abstract [en]

Background: Antenatal depression and use of serotonin reuptake inhibitors (SSRI) in pregnancy have both been associated with an increased risk of poor pregnancy outcomes, such as preterm birth and impaired fetal growth. While the underlying biological pathways for these complications are poorly understood, it has been hypothesized that inflammation may be a common physiological pathway. The aim of the present study was to assess peripheral inflammatory markers in healthy women, women with antenatal depression, and in women using SSRI during pregnancy.

Methods: 160 healthy pregnant controls, 59 women with antenatal depression and 39 women on treatment with SSRIs were included. The relative levels of 92 inflammatory proteins were analyzed by proximity extension assay technology.

Results: Overall, 23 of the inflammatory markers were significantly lower in women with antenatal depression and in women on treatment with SSRIs in comparison with the healthy controls. No difference in any of the inflammatory markers was observed between women with antenatal depression and those who were using SSRI. Top three inflammatory markers that were down-regulated in women with antenatal depression were TNF-related apoptosis-inducing ligand (TRAIL), p = 0.000001, macrophage colony-stimulating factor 1 (CSF-1), p = 0.000004, and fractalkine (CX3CL1), p =0.000005. Corresponding inflammatory markers in SSRI users were CSF-1, p = 0.000011, vascular endothelial growth factor A (VEGF-A), p =0.000016, and IL-15 receptor subunit alpha (IL-15RA), p = 0.000027. The inflammatory markers were negatively correlated with cortisone serum concentrations in controls, but not in the cases. Differential DNA methylation of was found for seven of these inflammatory markers in an independent epigenetics cohort.

Conclusion: Women with antenatal depression or on SSRI treatment have lower levels of a number of peripheral inflammatory markers than healthy pregnant controls. Hypothetically, this could be due to dysregulated switch to the pro-M2 milieu that characterizes normal third trimester pregnancy. However, longitudinal blood sampling is needed to elucidate whether the presumably dysregulated M2 shift is driving the development of antenatal depression or is a result of the depression.

Place, publisher, year, edition, pages
PERGAMON-ELSEVIER SCIENCE LTD, 2017
Keywords
Antenatal depression, Pregnancy, Inflammatory markers, Proximity extension assay, Selective serotonin reuptake inhibitors
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-326211 (URN)10.1016/j.psyneuen.2017.02.027 (DOI)000402352200003 ()28292683 (PubMedID)
Available from: 2017-08-08 Created: 2017-08-08 Last updated: 2017-08-08Bibliographically approved
Syk, M., Ramklint, M., Fredriksson, R., Ekselius, L. & Cunningham, J. L. (2016). Elevated total plasma-adiponectin is stable over time in young women with bulimia nervosa. European psychiatry, 41, 30-36, Article ID S0924-9338(16)30152-3.
Open this publication in new window or tab >>Elevated total plasma-adiponectin is stable over time in young women with bulimia nervosa
Show others...
2016 (English)In: European psychiatry, ISSN 0924-9338, E-ISSN 1778-3585, Vol. 41, p. 30-36, article id S0924-9338(16)30152-3Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Bulimia nervosa (BN) is characterized by dysregulated eating behaviour and present data suggest adipokines may regulate food intake. We investigated a possible association between BN and adipokine levels and hypothesized that plasma (P)-adiponectin would be elevated and P-leptin and P-leptin-adiponectin-ratio would be reduced in women with BN.

METHODS: The study was designed as a cross-sectional study with a longitudinal arm for patients with BN. Plasma-adiponectin and leptin was measured in 148 female patients seeking psychiatric ambulatory care and 45 female controls. Fifteen patients were diagnosed with BN and the remaining with other affective and anxiety disorders. P-adiponectin and P-leptin levels were compared between patients with BN, patients without BN and controls. At follow-up 1-2years later, adipokines were reassessed in patients with BN and the Eating Disorder Examination Questionnaire was used to assess symptom severity.

RESULTS: P-adiponectin was elevated in patients with BN at baseline and at follow-up when compared to patients without BN and controls (P<0.004 and <0.008 respectively). The difference remained significant after controlling for body mass index. P-adiponectin was correlated to symptom severity at follow-up in patients with BN without morbid obesity (ρ=0.72, P<0.04). P-leptin-adiponectin-ratio was significantly lower in patients with BN compared to controls (P<0.04) and P-leptin non-significantly lower.

CONCLUSIONS: Findings indicate a stable elevation of P-adiponectin in women with BN. P-adiponectin at follow-up correlates to eating disorder symptom severity in patients without morbid obesity, indicating that P-adiponectin should be further investigated as a possible potential prognostic biomarker for BN.

Keywords
Adiponectin, Biomarker, Bulimia nervosa, Leptin, Prognosis
National Category
Psychiatry
Identifiers
urn:nbn:se:uu:diva-318532 (URN)10.1016/j.eurpsy.2016.09.006 (DOI)000397668400006 ()28049078 (PubMedID)
Funder
Swedish Society of Medicine
Available from: 2017-03-25 Created: 2017-03-25 Last updated: 2017-04-19Bibliographically approved
Sundberg, I., Ramklint, M., Stridsberg, M., Papadopoulos, F. C., Ekselius, L. & Cunningham, J. L. (2016). Salivary Melatonin in Relation to Depressive Symptom Severity in Young Adults.. PLoS ONE, 11(4), Article ID e0152814.
Open this publication in new window or tab >>Salivary Melatonin in Relation to Depressive Symptom Severity in Young Adults.
Show others...
2016 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 11, no 4, article id e0152814Article in journal (Refereed) Published
Abstract [en]

Reduced levels of melatonin have been associated with severe depression. The aim was to investigate the correlation between salivary melatonin and dimensional measures of depressive symptom severity in young adult psychiatric patients. Levels of melatonin were analyzed in six saliva samples during waking hours from 119 young adult patients under outpatient psychiatric care. Melatonin levels were tested for association with the severity of depressive symptoms using the self-rating version of the Montgomery Åsberg Depression Rating Scale (MADRS-S). Where possible, depressive symptoms were assessed again after 6±2 months of treatment. Response was defined as decrease in MADRS-S by ≥50% between baseline and follow-up. Patients with levels of melatonin in the lowest quartile at bedtime had an increased probability of a high MADRS-S score compared to those with the highest levels of melatonin (odds ratio 1.39, 95% CI 1.15-1.69, p<0.01). A post hoc regression analysis found that bedtime melatonin levels predicted response (odds ratio 4.4, 95% CI 1.06-18.43, p<0.05). A negative relationship between salivary melatonin and dimensional measures of depressive symptom severity was found in young patients under outpatient psychiatric care. Bedtime salivary melatonin levels may have prognostic implications.

Keywords
Melatonin, Depression, Depressive Symptoms, Saliva, Severity, Prognosis, MADRS-S, Sheehan Disability Scale, HbA1C, Oxi-LDL, Research Domain Criteria (RDoC)
National Category
Psychiatry Neurosciences
Research subject
Psychiatry
Identifiers
urn:nbn:se:uu:diva-291425 (URN)10.1371/journal.pone.0152814 (DOI)000373592100035 ()27042858 (PubMedID)
Projects
Uppsala Psykiatriska Provsamling
Funder
Swedish Society of Medicine
Available from: 2016-05-02 Created: 2016-05-02 Last updated: 2018-01-10Bibliographically approved
Karpyak, V., Biernacka, J., Geske, J., Jenkins, G., Cunningham, J., Rueegg, J., . . . Choi, D. (2015). CLINICAL AND GENETIC MARKERS ASSOCIATED WITH THE LENGTH OF SOBRIETY IN HUMAN ALCOHOLICS TREATED WITH ACAMPROSATE. Paper presented at 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism, JUN 20-24, 2015, San Antonio, TX. Alcoholism: Clinical and Experimental Research, 39, 295A-295A
Open this publication in new window or tab >>CLINICAL AND GENETIC MARKERS ASSOCIATED WITH THE LENGTH OF SOBRIETY IN HUMAN ALCOHOLICS TREATED WITH ACAMPROSATE
Show others...
2015 (English)In: Alcoholism: Clinical and Experimental Research, ISSN 0145-6008, E-ISSN 1530-0277, Vol. 39, p. 295A-295AArticle in journal, Meeting abstract (Other academic) Published
National Category
Pharmacology and Toxicology
Identifiers
urn:nbn:se:uu:diva-266164 (URN)000361637102067 ()
Conference
38th Annual Scientific Meeting of the Research-Society-on-Alcoholism, JUN 20-24, 2015, San Antonio, TX
Available from: 2015-11-10 Created: 2015-11-05 Last updated: 2018-01-10Bibliographically approved
Söderquist, F., Hellström, P. M. & Cunningham, J. L. (2015). Human Gastroenteropancreatic Expression of Melatonin and Its Receptors MT1 and MT2. PLoS ONE, 10(3), Article ID e0120195.
Open this publication in new window or tab >>Human Gastroenteropancreatic Expression of Melatonin and Its Receptors MT1 and MT2
2015 (English)In: PLoS ONE, ISSN 1932-6203, E-ISSN 1932-6203, Vol. 10, no 3, article id e0120195Article in journal (Refereed) Published
Abstract [en]

Background and Aim The largest source of melatonin, according to animal studies, is the gastrointestinal (GI) tract but this is not yet thoroughly characterized in humans. This study aims to map the expression of melatonin and its two receptors in human GI tract and pancreas using microarray analysis and immunohistochemistry. Method Gene expression data from normal intestine and pancreas and inflamed colon tissue due to ulcerative colitis were analyzed for expression of enzymes relevant for serotonin and melatonin production and their receptors. Sections from paraffin-embedded normal tissue from 42 individuals, representing the different parts of the GI tract (n= 39) and pancreas (n= 3) were studied with immunohistochemistry using antibodies with specificity for melatonin, MT1 and MT2 receptors and serotonin. Results Enzymes needed for production of melatonin are expressed in both GI tract and pancreas tissue. Strong melatonin immunoreactivity (IR) was seen in enterochromaffin (EC) cells partially co-localized with serotonin IR. Melatonin IR was also seen in pancreas islets. MT1 and MT2 IR were both found in the intestinal epithelium, in the submucosal and myenteric plexus, and in vessels in the GI tract as well as in pancreatic islets. MT1 and MT2 IR was strongest in the epithelium of the large intestine. In the other cell types, both MT2 gene expression and IR were generally elevated compared to MT1. Strong MT2, IR was noted in EC cells but not MT1 IR. Changes in gene expression that may result in reduced levels of melatonin were seen in relation to inflammation. Conclusion Widespread gastroenteropancreatic expression of melatonin and its receptors in the GI tract and pancreas is in agreement with the multiple roles ascribed to melatonin, which include regulation of gastrointestinal motility, epithelial permeability as well as enteropancreatic cross-talk with plausible impact on metabolic control.

National Category
Neurosciences
Identifiers
urn:nbn:se:uu:diva-252709 (URN)10.1371/journal.pone.0120195 (DOI)000352134700057 ()25822611 (PubMedID)
Available from: 2015-05-12 Created: 2015-05-11 Last updated: 2018-01-11Bibliographically approved
Schalling, M., Engberg, G., Andreassen, O. A., Erhardt, S., Cunningham, J., Agartz, I., . . . Fatouros-Bergman, H. (2015). Nya rön om schizofreni kan ge ny diagnostik och behandling. Läkartidningen, 112, Article ID DH34.
Open this publication in new window or tab >>Nya rön om schizofreni kan ge ny diagnostik och behandling
Show others...
2015 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 112, article id DH34Article in journal (Refereed) Published
National Category
Psychiatry
Identifiers
urn:nbn:se:uu:diva-278147 (URN)
Available from: 2016-02-23 Created: 2016-02-23 Last updated: 2017-11-30Bibliographically approved
Karpyak, V. M., Preuss, U. W., Geske, J., Winham, S. J., Cunningham, J. M., Bakalkin, G. & Biernacka, J. M. (2014). Pdyn Rs2281285 Variat Is Associated With The Length Of Sobriety In Alcohol Dependent Subjects. Paper presented at 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA), JUN 21-25, 2014, Bellevue, WA. Alcoholism: Clinical and Experimental Research, 38, 148A-148A
Open this publication in new window or tab >>Pdyn Rs2281285 Variat Is Associated With The Length Of Sobriety In Alcohol Dependent Subjects
Show others...
2014 (English)In: Alcoholism: Clinical and Experimental Research, ISSN 0145-6008, E-ISSN 1530-0277, Vol. 38, p. 148A-148AArticle in journal, Meeting abstract (Other academic) Published
National Category
Pharmaceutical Sciences Neurosciences
Identifiers
urn:nbn:se:uu:diva-228884 (URN)000337523700592 ()
Conference
37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA), JUN 21-25, 2014, Bellevue, WA
Available from: 2014-07-23 Created: 2014-07-22 Last updated: 2018-01-11Bibliographically approved
Cui, T., Tsolakis, A. V., Cunningham, J., Li, S.-C., Lind, T., Öberg, K. & Giandomenico, V. (2013). Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis of Small Intestine Neuroendocrine Tumors. Paper presented at 5th Annual Meeting of the North American NeuroEndocrine Tumor Society, October 11–13, 2012, San Diego, California. Pancreas, 42(2), 373-373
Open this publication in new window or tab >>Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis of Small Intestine Neuroendocrine Tumors
Show others...
2013 (English)In: Pancreas, ISSN 0885-3177, E-ISSN 1536-4828, Vol. 42, no 2, p. 373-373Article in journal, Meeting abstract (Other academic) Published
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-197216 (URN)000314975200051 ()
Conference
5th Annual Meeting of the North American NeuroEndocrine Tumor Society, October 11–13, 2012, San Diego, California
Available from: 2013-03-19 Created: 2013-03-19 Last updated: 2017-12-06Bibliographically approved
Organisations

Search in DiVA

Show all publications